Chemours (CC) stock is experiencing a significant pre-market plunge of 10.83% following the release of its disappointing first-quarter 2025 earnings report and several concerning announcements that have shaken investor confidence.

The chemical manufacturer reported adjusted earnings per share (EPS) of $0.13 for Q1, falling well short of the analyst consensus estimate of $0.21. This represents a substantial 59.38% decrease compared to the same period last year. Despite beating revenue expectations with Q1 sales of $1.37 billion, slightly above the projected $1.34 billion, Chemours swung to a loss of $4 million in the quarter, compared to a profit of $54 million a year earlier.

Adding to investor concerns, Chemours announced a drastic 65% reduction in its quarterly dividend to $0.0875 per share, citing the need to better align its capital allocation and achieve balance sheet flexibility. Furthermore, the company lowered the top end of its full-year adjusted EBITDA guidance to between $825 million and $950 million, down from the previous upper range of $975 million. CEO Denise Dignam acknowledged that the company faced both macroeconomic and business-related headwinds across all three of its main businesses, contributing to the disappointing results and cautious outlook.